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Prognosis for patients with anaplastic gliomas (glioblastoma anti-herpes-virus drug in herpes-simplex encephalitis (Muller multiforme, astrocytoma IV) is poor: median survival times Whitley et al., 1977) . ARA-A5'P (MW=335) for surgery, radiotherapy and BCNU are 34.5 to 51 weeks penetrates the BBB very well, resulting in CSF levels of 60% (Walker et al., 1978; Walker et al., 1980) ; only a small of the concurrent plasma levels (LePage et al., 1975;  proportion of patients will survive longer than 18 months. In Preiksaitis et al., 1981; Whitley et al., 1980) . Its main modes vitro assay systems have been developed to detect of action are competitive inhibition of cellular and viral chemotherapy responders, to define alternative drug DNA replication systems, inhibition of the cellular DNA regimens for non-responding patients, to avoid subjecting repair system, inhibition of ribonucleotide reductase, patients to the toxicity of unnecessary chemotherapy, and inhibition of DNA-and RNA-directed DNA-synthesis, finally to screen for new potentially acti've agents. Some in inhibition of adenylate-polymerase and finally incorporation vitro systems showed a reasonable correlation with clinical into cellular and viral DNA and RNA (Muiller et al., 1977) . courses of patients, whose brain tumours had been tested Preliminary evidence of an anti-glioma activity of ARA-A5'P (Bogdahn, 1983; Rosenblum et al., 1983; Thomas et al., has been deduced from previous in vitro work with ARA-A, 1979) . However, the poor permeability of most drugs indicating efficacy in a number of brain tumours (Bogdahn, through the blood brain barrier (BBB), and resulting brain 1983); the purpose of the preceding paper was mainly to tumour exposure doses were not calculated. Therefore it was delineate a potential activity of ARA-A5'P in human brain extremely difficult to estimate adequate in vitro tumour cells and to compare it with that of VM26 and concentrations for the various screening procedures. In this BCNU, in order to estimate its potential relevance for paper we have tried to reduce these limitations by strictly clinical therapy. correlating in vivo and in vitro pharmacokinetic data (exposure doses) of BCNU, VM26 and ARA-A5'P, whenever possible applying CNS drug data.
Materials and methods
We choose BCNU (carmustine; MW = 218), mainly an alkylating and carbamoylating, as well as DNA-crosslinking, Cell cultures non cell cycle-phase specific agent (Tofilon et al., 1983) penetration of the BBB is poor (Allen et at., 1975) , but drug After preparation of a cell suspension in complete tissue concentrations in brain tumour tissue have been determined culture medium (MEM, 20% FCS, 6 ugml-1 gentamycin, (Stewart et at., 1984) . Clinical results with this drug have 1 mmol P1 L-glutamine, non-essential amino-acids and been controversial (Jamamoto et at., 1979; Kettinger et at., MEM-vitamins -Boehringer-Mannheim) Eng et al., 1971 ; S-100, fibronectin, neurone-specific enolase, transferrin-receptor, melanoma-associated antigen, keratinDakopatts; HLA-A,B,C, HLA-DR-Becton-Dickinson) and by cytogenetic analysis (karyotyping) (Bogdahn et al., 1985; Bogdahn et al., in preparation) . Glial tumours expressed at least 3 of the typical antigens GFAP, Ge-2, S-100, Thy-I or melanoma-associated antigens, usually in a nonhomogeneous pattern. Karyotypes were always pathological, most cultures displayed near diploid karyotypes. Neuropathological diagnosis of biopsies from which cultures were derived are given in Table I .
Assay systems
Experiments to assess drug activity in different cell cultures were performed with a microassay (Bogdahn, 1983; Bogdahn et al., 1985) : Single cells were plated into 96-well micro-tissue culture plates (flat bottom -Costar) in complete tissue culture medium. After 24h cells were treated with different drugs either for 1 h or continuously, dependening on the cellcycle phase specificity of individual drugs (see below). They were then allowed to proliferate under tissue culture conditions for 5 to 8 population doubling times of untreated controls, equalling 7 to 14 days (there was no correlation of population doubling times to chemosensitivity); finally [5,6-3H] (Allen et al., 1975; Stewart et al., 1984 Table III , clearly metastatic brain tumours are less sensitive to all 3 agents than primary CNS neoplasms. Cell cultures with SI-values lower than 0.8, 0.5 and 0.2 are also depicted in Table IV . Sensitivity indices of each cell line for the 3 different drugs are depicted in Figure 4 . If sensitivity indices of the 3 different drugs were compared on a statistical basis for each individual cell line, ARA-A5'P and VM26 were significantly more effective against brain tumour cell lines than BCNU (P<0.001). Differences between ARA-A5'P and VM26 were not significant. Cell cultures were also analysed for histology-related chemosensitivity (Table V) : High grade malignant brain tumours generally were more resistant to the 3 drugs than low grade and infratentorial tumours.
Drug effects of ARA-A5'P on tumour colony progenitor cells were comparable to the effects seen in the micro-assay: results for 3 different cell lines may be seen in Table VI; colony formation was significantly inhibited by ARA-A5'P at a concentration of 15 ,imol 1-1. 
Discussion
This study was intended to compare the anti-brain tumour activities of BCNU, with VM26, which is currently under clinical investigation for treatment of this class of tumour, and ARA-A5'P, which has not yet been used for treatment of CNS neoplasms. An in vitro comparative study was performed with a microsystem that had earlier shown a good correlation between in vitro chemosensitivities of human malignant brain tumour cells towards BCNU and the clinical course of patients being treated with nitrosoureas (Bogdahn, 1983) . In this present study 3 out of 21 primary brain tumour cell lines (14.3%) displayed high sensitivity to BCNU (SI<0.2). This proportion correponds to the number of longterm survivors among patients with anaplastic gliomas treated with BCNU (Liebermann et al., 1982; Walker et al., 1978 Walker et al., , 1980 . As clinical results for BCNU chemotherapy in brain tumour patients were reproduced fairly consistently in several clinical trials, and in vitro results were in good concordance with clinical experience, BCNU was chosen as a drug of reference in this in vitro investigation.
The results of previous clinical studies (Jamamoto et al., 1979; Kettinger et al., 1979) on the activity of VM26 on human malignant brain tumours are controversial; our results indicate high in vitro activity of this compound, superior to that of BCNU. Pharmacokinetic parameters for our experiments have respected the dose modifying effects of the BBB on VM26-brain tumour tissue concentrations under experimental conditions (Stewart et al., 1984) ; the clinical mode of application (30min infusion) should be reconsidered critically -perhaps a continuous infusion might reflect the drugs cell cycle phase specific activity in an optimal fashion.
Preliminary observations indicate anti-tumour activity of ARA-A5'P in in vitro systems (Bogdahn, 1983; Kufe et al., 1983) and in some animal tumour systems (Bodey et al., 1975 (Bodey et al., , 1977 . From previous studies on pharmacology (LePage et al., 1975; Preiksaitis et al., 1981) and on treatment of herpes simplex encephalitis (Whitley et al., 1977) , the drug was known to have a high permeability through the BBB ('60% of concurrent plasma levels may be found in the CSF). For these reasons ARA-A5'P seemed to be an attractive drug for further studies on activity against brain tumour cells. As variations in individual patients serum deaminase activity result in variable drug inactivation, we have employed only one fifth of the maximum achievable in vivo concentration time product for in vitro experiments; so drug activity demonstrated in our experiments will even reflect that activity that may be anticipated in those patients with extremely high serum deaminase activity and rapid drug inactivation. In this study we could clearly demonstrate that ARA-A5'P has high activity against human malignant glial tumour cells in vitro, since it was significantly more active (P<0.001) than BCNU (see Tables I, III , IV, Figure 5 ). It was less active in metastatic brain tumours than in primary brain tumour cells, which was also the case for the other 2 drugs we tested. In these experiments we did not find an indication for crossresistance of ARA-A5'P to either VM26 or BCNU. In addition, ARA-A5'P was able to inhibit growth of brain tumour colony progenitor cells in a comparable fashion to the results obtained with the microassay (Table VI) .
Compared to BCNU, which has rather significant pulmonary, renal, and bone marrow toxicity (MacDonald et al., 1981; West et al., 1983) , ARA-A5'P appears to be less toxic. Its toxic side effects (bone marrow depression, hepatotoxicity, CNS toxicity -tremor and myoclonus) were all reversible within 2 weeks at most and observed mainly under extremely high dosage (Preiksaitis et al., 1981; Whitley et al., 1980; Kurtz, 1975) . Insufficient renal function may require dose reduction of the compound.
In conclusion, we could demonstrate high activity of ARA-A5'P in human brain tumour cell lines in vitro. This compound has excellent pharmacokinetic characteristics for prospective application as a chemotherapeutic agent in brain tumour therapy, it is relatively well tolerated and rather nontoxic compared to BCNU; its activity is significantly superior to BCNU in our experiments and comparable to the activity of VM26. As a result of this study we propose that ARA-A5'P should be considered for future clinical investigation in brain tumour therapy. In vitro results with VM26 indicate higher in vitro activity than found clinically so far -a proposal is made for a modified clinical drug application as a continuous application rather than a bolus infusion. We could also demonstrate that there is a proportion of metastatic brain tumours which is chemosensitive to agents active against primary CNS neoplasms; individual chemosensitivity screening might be helpful to identify these potential chemotherapy responders.
